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WHAT’S NEW 
Our large prospective study strengthens the evidence for weak positive associations of 
blood pressure with the risk of cancers in several locations: kidney, colon and post-
menopausal breast cancers, and with some specific morphologies: squamous cell carcinoma 
(SCC) in the upper aero-digestive tract and skin and adenocarcinoma in corpus uteri. We also 
report weak inverse associations with lymphomas and cervical SCC. Our findings render 
plausible a hypothesis of shared mechanisms for hypertension and cancer development. 
KEY WORDS 
cancer, hypertension, morphology, cohort, Europe, epidemiology, association, risk factors 
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ABBREVIATIONS 
AC - adenocarcinoma   
ASH - American Society of Hypertension     
BP - blood pressure      
CI - confidence interval 
DBP - diastolic blood pressure 
EPIC - European Prospective Investigation into Cancer and Nutrition 
ESH - European Society of Hypertension 
HCC - hepatocellular carcinoma 
HR - hazard ratio 
MBP - mean blood pressure, derived as (1/3)*SBP+(2/3)*DBP (used in the current study) 
Me-Can - Metabolic syndrome and Cancer project 
mid-BP - mid-blood pressure, derived as the mean of SBP and DBP (used in Me-Can) 
OR - odds ratio 
RCC - renal cell carcinoma 
RR - risk ratio 
SBP - systolic blood pressure  
SCC - squamous cell carcinoma 
SD - standard deviation
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ABSTRACT 
Several studies have reported associations of hypertension with cancer, but not all 
results were conclusive. We examined the association of systolic (SBP) and diastolic (DBP) 
blood pressure with the development of incident cancer at all anatomical sites in the 
European Prospective Investigation into Cancer and Nutrition (EPIC). Hazard ratios (HR) 
(95% confidence intervals) were estimated using multivariable Cox proportional hazards 
models, stratified by EPIC-participating centre and age at recruitment, and adjusted for sex, 
education, smoking, body mass index, physical activity, diabetes and dietary (in women also 
reproductive) factors. The study included 307,318 men and women, with an average follow-
up of 13.7 (standard deviation 4.4) years and 39,298 incident cancers. We confirmed the 
expected positive association with renal cell carcinoma: HR=1.12 (1.08-1.17) per 10mmHg 
higher SBP and HR=1.23 (1.14-1.32) for DBP. We additionally found positive associations 
for esophageal squamous cell carcinoma (SCC): HR=1.16 (1.07-1.26) (SBP), HR=1.31 (1.13-
1.51) (DBP),  weaker for head and neck cancers: HR=1.08 (1.04-1.12) (SBP), HR=1.09 
(1.01-1.17) (DBP) and, similarly, for skin SCC, colon cancer, post-menopausal breast cancer 
and uterine adenocarcinoma (AC), but not for esophageal AC, lung SCC, lung AC, or uterine 
endometroid cancer. We observed weak inverse associations of SBP with cervical SCC: 
HR=0.91 (0.82-1.00) and lymphomas: HR=0.97 (0.93-1.00). There were no consistent 
associations with cancers in other locations. 
Our results are largely compatible with published studies and support weak associations of 
blood pressure with cancers in specific locations and morphologies. 
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INTRODUCTION 
Hypertension and cancer are complex multifactorial conditions. Hypertension is a 
worldwide public health challenge, with systolic blood pressure (SBP) above 115mmHg 
ranked as the leading risk factor for the global burden of disease in 2017 [1]. The global age-
standardised prevalence of raised blood pressure (SBP≥140mmHg or diastolic BP 
DBP≥90mmHg) in adults was estimated as ≥20% in 2015 [2]. However, whilst hypertension 
is a major risk factor for coronary heart disease and stroke, the evidence is much weaker for 
an association with cancer [3]. 
A meta-analysis of ten longitudinal studies published in 2002 found that individuals 
with hypertension had higher risk of total cancer mortality: odds ratio OR=1.23 (95% 
confidence interval (CI) 1.11-1.36), largely explained, based on 13 case-control studies, by a 
positive association for renal cell carcinoma (RCC) mortality: OR=1.75 (1.61-1.90) [4]. The 
results of subsequent studies have confirmed that hypertension is associated with a higher 
incidence of RCC [5-8]. Whilst, hypertension has not attracted much attention as a risk factor 
for other cancers, recent meta-analyses of observational studies, although summarising only 5 
to 12 prospective studies and with large between-study heterogeneity, have reported higher 
risks for endometrial, prostate, postmenopausal breast and colorectal cancer, comparing 
hypertensive with normotensive participants [9-15]. Further, the largest to date prospective 
study examining the association of individual components of the metabolic syndrome 
(including BP measurements) and cancer in over half a million participants from Norway, 
Sweden and Austria: the Metabolic syndrome and Cancer project (Me-Can) [16], reported 
positive associations of high BP with the risk of cancers in locations other than the kidney in 
both men (oropharynx, colon, rectum and anus, lung with larynx and trachea, bladder, 
malignant melanoma, non-melanoma skin cancer) and women (liver, pancreas, corpus uteri, 
cervix, malignant melanoma) [3]. 
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It is not clear whether the association of hypertension with cancer is causal or it could, 
at least partially, be explained by reverse causality or other biases. It is, however, possible 
that risk factors and mechanisms of pathogenesis are shared by the two conditions. For 
example, it has been hypothesized that predisposition to cancer is increased by chronic 
inflammation [17] and vascular inflammation could be involved in the pathogenesis of 
hypertension [18]. Lipid peroxidation, associated with hypertension and obesity, has also 
been proposed as a mechanism responsible for higher risk of RCC [19]. Further, experimental 
studies have implicated a potential role of the renin-angiotensin-aldosterone system (which 
regulates BP) in the biological processes of cellular proliferation, inflammation, 
angiogenesis, and tissue remodeling [20]. Studies in mice have also provided preliminary 
evidence that blockade of the angiotensin II type 1 receptor attenuates the growth and 
metastatic potential of RCC [21]. 
In the context of the above considerations, the aim of our study was to further explore 
the association between hypertension and cancer. We examined whether measured SBP and 
DBP were associated with the risk of incident cancer at all anatomical sites in the large and 
well-established European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, 
after taking into account obesity smoking and other lifestyle and dietary factors (for both men 
and women) and indicators of sexual maturation and reproductive life (for women), which 
could be potential confounders or shared risk factors for cancer and hypertension. 
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MATERIALS AND METHODS 
Study population 
EPIC is an ongoing, multicentre, prospective cohort study designed to investigate the 
associations between diet, lifestyle, and various medical and environmental risk factors with 
the incidence of cancer and other diseases. The source population (the majority aged between 
25 and 70 years at the time of enrolment) and data collection methods have been described in 
detail previously [22]. Approval for this study was obtained from the ethical review boards of 
the International Agency for Research on Cancer and from all the EPIC participating centres. 
Written informed consent was obtained from all participants before entry into the study. 
Figure 1 shows a detailed flow-chart of study participants with exclusions. 
Assessment of blood pressure and other variables 
SBP and DBP were measured in millimeters of mercury (mmHg) by trained 
personnel. Measurements were obtained during a visit to an EPIC centre and within 6 months 
of recruitment in 91.5% of participants, except in France: all measurements obtained at the 
blood-collection visit, 3.8 years (standard deviation (SD) 1.3) after recruitment; Granada: 
39.2% after 2.0 (0.9) years; San Sebastian: 78.4% after 1.6 (0.7) years; Oxford: 29.3 % after 
0.8 (0.2) years. Two readings (1-5 minutes apart) were performed with a standard mercury 
manometer or oscillometric device on the right arm in a sitting position (after at least 5 
minutes initial resting time). The average value was used as the exposure variable, assuming 
differences are due to random measurement error. Exceptions were the Danish and Swedish 
centres, where one single measurement was taken in the supine position. Mean BP (MBP) 
was defined as (1/3)*SBP+(2/3)*DBP [23] and not as the mean of SBP and DBP (mid-BP), 
used in the Me-Can study [3]. Self-reported information on treatment with antihypertensive 
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medication (at baseline and/or in the past) was available for 264,353 participants (86.9%), of 
which 37,017 (14%) were receiving or had received treatment. 
Information on socio-demographics, lifestyle characteristics, medical history and 
dietary intake was collected via questionnaires at the time of recruitment. Weight and height 
were measured at recruitment using a standardised protocol, except for part of the Oxford 
cohort and France, where height and weight were self-reported. Body mass index (BMI) was 
calculated as weight/height
2
 (kg/m
2
). Food and nutrient intakes were estimated from country-
specific baseline dietary questionnaires [22]. A physical activity index was derived as 
previously described [24]. 
Assessment of cancer 
Incident cancer cases were identified through population cancer registries in 
Denmark, Italy, the Netherlands, Spain, Sweden and the United Kingdom. In France, 
Germany and Greece, a combination of methods was used including health insurance records, 
cancer pathology registries and active follow-up of study participants and their next of kin. 
Cancer incidence data were coded according to the International Classification of Diseases 
for Oncology (ICD-O) [25]. The presented analyses are focused on the first primary 
neoplasm. Participants subsequently diagnosed with a second (or third) cancer, were censored 
at the date of diagnosis of the first cancer. We considered a joint group of any cancer and 
location (ICD-O behavioral code 3 (malignant, primary site)) and separate groups for all 
major anatomic sites (excluding rare morphologies), with further subdivisions for specific 
locations or major morphologies (Supplementary Table 1).  
Statistical analyses 
Hazard ratios (HRs) (95% CIs) were estimated using delayed-entry Cox proportional 
hazards models, with age at recruitment (5-year categories) and EPIC centre (n=25) as 
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stratification variables. Origin of time was the date of birth, aligning individuals by birth 
cohort. Entry time was the date of BP measurement. Time of censorship was the date of first 
incidence of cancer (recruitment to 2013), or death, or last complete follow-up, whichever 
occurred first. 
The main analyses examined the following exposures: SBP and DBP (considered in 
separate models and each as a continuous (per 10mmHg) variable); hypertension (defined as 
a dichotomous (yes/no) variable, according to BP measurements (SBP≥140mmHg, or 
DBP≥90mmHg) or self-reported information, and antihypertensive treatment in hypertensive 
individuals (a binary variable defined according to self-reported antihypertensive treatment 
(yes/no) for individuals fulfilling the hypertension criteria specified above). The latter 
analysis aimed to examine potential associations of antihypertensive drugs, as exogenous 
chemicals, and cancer. Although the results for hypertension (yes/no) would be useful for 
meta-analyses, the risk estimates per 10 mmHg, based on the complete range of SBP and 
DBP, would be more informative than a dichotomous simplification. The secondary analyses 
examined SBP and DBP as categorical variables, with categories based on the definitions of 
the American (ASH) [26] and the European Society of Hypertension (ESH) [27] 
(Supplementary Table 2), and MBP, as a continuous variable and also categorised using 
cohort-wide quartiles (cut-points at 88.8, 96.7, 106.0 mmHg). To test for trend, BP categories 
were analysed as continuous variables, after assigning participants an ordinal score. 
All statistical models were adjusted for the categorical variables listed in 
Supplementary Table 2. Missing values were assigned to separate categories. For pre-
menopausal breast cancers, analyses were restricted to participants with pre-menopausal 
status at recruitment (if known), or under the age of 46 (for unknown menopausal status) and 
were not adjusted for menopausal status or age at menopause. If breast cancer diagnosis was 
before 46 years of age, participants were considered “cases”, otherwise they were censored at 
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46 years, if not censored by age 46 for death, loss to follow-up or other cancer. For post-
menopausal breast cancer, analyses were restricted to participants with physiological or 
surgical menopause at recruitment, or with age≥55 years (for unknown menopausal status). 
Additionally, associations of BP with cancer were examined in strata according to age 
(cut-point at 53 years, the cohort-wide median), sex, BMI (cut-point at 25kg/m
2
), smoking 
status (ever smokers vs never smokers), alcoholic beverages intake (cut-point at 12g 
ethanol/day, the largest ethanol unit used in Europe) and use of antihypertensive treatment in 
individuals with available information for the stratifying factor. Likelihood ratio tests, 
comparing nested models with and without the addition of interaction terms, were used to test 
for statistical interactions on multiplicative scale. BP categories were included in the 
interaction models as ordinal variables. Examining potential biological interactions was 
beyond the scope of this study. 
Sensitivity analyses were also performed, excluding the first two years of follow-up 
(to explore possible reverse causation). Crude estimates of HR (omitting the adjustment 
variables, but retaining the stratification by age at recruitment and study centre) were 
calculated to examine the influence of adjustment. 
All analyses were performed with STATA version 13 software. Plots and data 
summaries were generated in R version 3.4.3. 
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RESULTS AND DISCUSSION 
Characteristics of study participants 
The study cohort consisted of 307,318 individuals (63.4% women), with a mean age 
52.5 (SD=9.9) years at recruitment. During an average follow-up of 13.7 (SD=4.4) years, 
39,298 incident cancers were diagnosed, with major anatomical sites: breast (n=8,154 cases), 
prostate (n=5,848), colorectum (n=4,625) and lung (n=3,229). Mean SBP was 131.5mmHg 
(SD=19.7) and mean DBP was 81.1mmHg (SD=10.9). BP measurements and numbers of 
cancer cases are summarised by country in Supplementary Table 3. Participants with higher 
SBP or DBP were older, more  likely to be men, to have low education or physical activity 
level, to have higher BMI, to have diabetes mellitus and to consume more alcohol and red 
meat, but less fruit and vegetables. Women with higher SBP or DBP were less likely to have 
ever used oral contraceptives. Cohort characteristics are summarised by hypertension and 
treatment status in Table 1 and by BP categories in Supplementary Table 4. 
Associations with the risk of malignant cancers 
Results from all analyses are included in Supplementary Table 5. The presentation 
below focuses on SBP and DBP examined as continuous variables in adjusted models. Forest 
plots with estimates of HR (95% CI) for SBP and DBP in the total dataset are shown in 
Figure 2; for hypertensive status and antihypertensive treatment in Figure 3 and for sub-
groups determined by sex, BMI, age at recruitment, smoking status, alcohol and 
antihypertensive treatment are shown in Supplementary Figure 1. There were positive 
associations of BP with malignant cancers in several locations and with some specific 
morphologies. Analyses of BP categories were largely in agreement with the findings for BP 
examined on a continuous scale. The main findings are presented below, within the context of 
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large published studies and meta-analyses. Anatomical cites and cancers, for which there was 
no overall association, are presented in Supplementary Results and Discussion. 
Kidney cancer and cancers of the renal pelvis and ureter 
The results of the current analyses confirmed our previous findings [6] of a positive 
association of BP with the risk of RCC: HR=1.12 (1.08-1.17) for SBP and HR=1.23 (1.14-
1.32) for DBP (Figure 2). We found no evidence for a difference between men (with n=431 
cases) and women (n=327) (Supplementary Figure 1A,B). As cancers of the renal pelvis and 
ureter are mainly of transitional cell morphology, i.e. different than the parenchymal cell 
morphology of RCC, they were considered as a negative control and, indeed, there was no 
association with BP in the total dataset (n=112). There was, however, an indication for a 
positive association with SBP in the subgroup with BMI>25kg/m
2
 (n=63): HR=1.16 (1.03-
1.32). The risk was also higher in treated compared to untreated hypertensive individuals: 
HR=2.21 (1.18-4.12) (Figure 3), although for a small number of cases. 
The association of hypertension with a higher risk of RCC is well established. In 
1999, Grossman et al. reported a higher risk for users of diuretics relative to nonusers: 
OR=1.55 (1.42-1.71), based on a meta-analysis of 9 case-control studies, and more than a 
two-fold increased risk, based on three cohort studies [28]. In 2007, a meta-analysis of 18 
studies reported a higher risk of RCC among hypertensive patients (estimated pooled 
OR=1.62 (1.24-2.12)), also for treatment with diuretics and, in women, with non-diuretic 
drugs [7]. At the same time, Weikert et al. reported, based on 250 cases in the EPIC study, 
that high SBP and DBP are associated with a higher risk of RCC, both in men and women 
and found that individuals receiving antihypertensive treatment had higher risk only if 
hypertension was poorly controlled [6]. Earlier, Heath et al. had reported in a large cohort 
high age-adjusted risk-ratio in women: RR=3.1 (1.5-4.3), but not in men: RR=0.8 (0.4-1.3) 
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receiving antihypertensive medication, including diuretics [29] and Grossman et al. had 
reported from a meta-analysis of seven case-control studies a high risk in women: averaged 
OR=2.01 (1.56-2.67), but slightly lower risk in men OR=1.69 (1.34-2.13), but with 
heterogeneity between the studies [28]. However, Haggström et al. reported for the Me-Can 
project a higher risk only in men (n=592): HR=1.39 (1.24-1.56) per 10mmHg higher mid-BP, 
but not in women (n=263): HR=1.05 (0.89-1.24) [3], with similar findings for SBP and DBP 
examined separately [30]. Nevertheless, a more recent meta-analysis of 18 prospective 
studies, with a total of 8097 cases, has confirmed an association of history of hypertension 
with kidney cancer: risk ratio estimate RR=1.67 (1.46-1.90) and an association also of SBP 
and DBP in both men and women [8], in agreement with our findings. A potential 
relationship between hypertension and the risk of renal pelvis and ureter cancer is less well 
studied, but an early case-control study reported a positive association for hypertension 
history longer than 5 years: OR=1.3 (1.0-1.8) and, in agreement with our findings, among 
users of antihypertensive drugs: OR=2.4 (1.1-4.9) [31]. However, as antihypertensive 
treatment may be related to the type and severity of hypertension, it is difficult to separate 
their effects in an observational study. 
Cancers of the upper aero-digestive tract and lung 
We found a positive association of BP with the risk of esophageal carcinoma, but 
more specifically with squamous cell carcinoma (SCC) (n=149): HR=1.16 (1.07-1.26) for 
SBP and HR=1.31 (1.13-1.51) for DBP and not with esophageal adenocarcinoma (AC) 
(n=176) (Figure 2). We also found a weak positive association for head and neck cancers 
(89% of which were SCC morphology): HR=1.08 (1.04-1.12) for SBP and HR=1.09 (1.01-
1.17) for DBP (similarly for mouth and oropharynx and for larynx). For mouth and 
oropharynx, the positive associations were statistically significant only in women, in 
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individuals older than 53 years at recruitment and for alcohol intake>12g/day and for head 
and neck cancers and esophageal SCC only for alcohol intake>12g/day and not below. There 
were, however, fewer cases among never smokers and the 95% CIs were too wide to make 
meaningful conclusions for smoking (Supplementary Figure 1G,H). 
For lung cancer, there was no overall evidence for association of BP with SCC, AC or 
small cell carcinoma morphologies (Figure 2). In subgroup analyses, we observed an inverse 
association of DBP with lung AC among individuals with BMI>25kg/m
2
 (n=528): HR=0.90 
(0.83-0.98) and a positive association of SBP with lung SCC in individuals receiving 
antihypertensive treatment (n=74): HR=1.14 (1.01-1.28). A weak positive association of SBP 
with the risk of total lung cancer was mainly accountable for by other morphologies 
(predominantly unclassified or large cell): HR=1.06 (1.02-1.09). 
Our findings for esophageal cancer are in agreement with the similarly-sized Me-Can project, 
for which Stocks et al. reported a positive association of mid-BP with total esophageal cancer 
(n=285): HR=1.33 (1.13–1.57) per 10mmHg higher BP [3]. Lindkvist et al. further showed 
that this was accountable for by a higher risk of SCC (n=184): HR=1.30 (1.17-1.44) and not 
AC (n=114): HR=1.03 (0.89-1.19), with no major differences between subgroups of never, 
former and current smokers [32]. For head and neck cancers, Stocks et al. did report for the 
Me-Can project an association of mid-BP with the risk of cancers of the lip, oral cavity and 
pharynx, but only in men (n=561): HR=1.31 (1.15-1.48) per 10mmHg increase, and not in 
women (n=177): HR=1.05 (0.85-1.28). They also found a positive association for the 
combined group of cancer of the larynx, trachea and lung in men (n=2810): HR=1.09 (1.03-
1.16) but not in women (n=905): HR=1.00 (0.92-1.10) [3]. Our study includes a similar 
number of lung cancer cases (n=3229), but we have examined separately cancer of the larynx 
and individual lung morphologies. Whilst smoking is a major risk factor for both esophageal 
and lung SCC cancers and can also lead to hypertension, as shown in an animal model [33] 
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and some epidemiological studies [34, 35], we could find a positive association with 
hypertension only for esophageal and not for lung SCC, after adjustment for smoking. If there 
was any residual confounding by smoking, it is likely that we would have observed a positive 
association for lung, as well as for esophageal SCC. In fact, we could find no positive 
association of hypertension with lung SCC even without adjustment for confounders (crude 
HRs in Supplementary Figure 2). Further, a positive association for esophageal AC was 
observed only in unadjusted analyses but was lost after adjustment for confounders, 
indicating that the adjustment, has removed, to a great extent, the confounding by smoking. 
This leads us to conclude that smoking is not likely to explain the association of high BP with 
the risk of SCC in the upper aero-digestive tract. Alcohol, however, may have an influence 
(Supplementary Figure 1I,J), but further investigations are needed to clarify our observations. 
Gastric and colorectal cancers 
We could not find association of BP with the risk of gastric cancer (n=738) (including 
gastric AC (n=403)) in the total cohort (Figure 2). We only found a positive association for 
gastric AC among individuals receiving antihypertensive treatment (n=53): HR=1.22 (1.06-
1.40) for SBP and HR=1.65 (1.27-2.15) for DBP. We also found a weak positive association 
of DBP with the risk of cancer of the colon (n=3003) (75% of which had AC (code 8140/3) 
morphology): HR=1.06 (1.02-1.10) for DBP, similarly for men and women (Supplementary 
Figure 1B), but not the rectum and rectosigmoid junction (n=1622) (81% AC) (Figure 2). 
There was also a weak positive association of SBP with the risk of colorectal cancer 
(similarly for colon and rectum (including rectosigmoid junction)) in men, but not in women 
(in men colon (n=1304): HR=1.03 (1.00-1.06) and rectum (n=876): HR=1.03 (0.99-1.07)). 
We also found a positive association in the subgroup analyses for participants with 
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BMI>25kg/m
2
 (colon: n=1813, rectum: n=966) and for the participants who reported alcohol 
intake>12g/d (colon: n=1091, rectum: n=685) (Supplementary Figure 1C,D,I,J). 
Our data are broadly compatible with results from previous large studies, which 
suggest that high BP is associated with the risk of colorectal cancer in men but not in women. 
In 2001 Tenenbaum et al. reported, in a cohort of patients with stable angina or previous 
myocardial infarction, higher risk of colon cancer (n=96) in individuals receiving diuretics 
compared to nonusers: HR=2.0 (1.2-3.2) [36]. More recently, in a large case-control study in 
Italy, Pelucchi et al. found that history of treated hypertension was associated with colorectal 
cancer risk in men (n=1310) OR=1.24 (1.03-1.48) but not in women (n=946) OR=0.87 (0.71-
1.06) [37]. Stocks et al., considering SBP, DBP and mid-BP in a prospective study (Me-Can), 
also reported a positive association for cancer of the colon in men (n=1747): HR=1.10 (1.03-
1.19) per 10mmHg higher mid-BP but not in women (n=1265): HR=0.95 (0.88-1.02) [3, 38], 
with similar findings for cancer of the rectum and anus [3]. Esposito et al., have subsequently 
reported in a meta-analysis based on 9 studies, a RR=1.09 (1.01-1.18) for high BP, although 
considering jointly men and women [13]. For gastric AC, Lindkvist et al., similar to our total 
cohort results, could not find in the Me-Can project evidence supporting an association with 
mid-BP (n=1210), but they did not consider antihypertensive treatment [39]. 
Breast cancer 
In our study, representing a cohort with the largest to date number of breast cancer 
cases, we found a weak but statistically significant positive association with both, SBP and 
DBP (n=8154): HR=1.03 (1.01-1.04) for SBP and HR=1.03 (1.01-1.06) for DBP. The 
association was similar for post-menopausal cancers (n=4786), but the number of pre-
menopausal cancers was considerably smaller and the 95% CIs were too wide to permit 
conclusions. In sub-group analyses, the positive association of SBP with the risk of post-
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menopausal breast cancer was retained only in ever smokers (n=2180) and there was some 
suggestion for a positive association of SBP with pre-menopausal breast cancer in women 
with alcohol intake≤12g/day (n=201) (Supplementary Figure 1G,I). 
Literature reports on breast cancer are conflicting. In an early case-control study in 
Italy, Soler at al. described a higher risk of breast cancer in women with treated hypertension 
(n=3,406): OR=1.2 (1.1-1.4) and more specifically in post-menopausal (n=2184), at age 55 
years or older (n=1580), in drinking women (n=2,400) and at BMI>25kg/m
2
 (n=1266) and 
not in pre- and peri-menopausal women [40]. However, Bjorge et al. in the Me-Can project 
did not find associations of SBP or DBP with the risk of incident breast cancer (n=4,862), 
however they reported a higher risk of breast cancer mortality for age≥60 years [41]. 
Similarly, Largent et al., defining high BP as treated hypertension in the California Teachers 
Study cohort (n=4,151), found a higher risk associated with antihypertensive treatment longer 
than 5 years: HR=1.18 (1.02-1.36) [42], but no association with hypertension overall. 
However, in the largest to date meta-analysis (n=11,643), Han et al. (in agreement with an 
earlier meta-analysis [12] and with our findings) have reported a higher risk of breast cancer 
in hypertensive women, based on 18 retrospective case-control studies: RR 1.29 (1.14-1.47) 
and on 12 prospective studies: RR=1.07 (1.01-1.14), but only for post-menopausal women 
(13 studies): RR=1.20 (1.09-1.31) and not for pre-menopausal (9 studies): RR=0.97 (0.84-
1.12) [15]. 
Endometrial cancer 
For cancers located in corpus uteri, we found a weak positive association, which 
could be traced only to AC morphology (code 8140/3): HR=1.06 (1.01-1.12) for SBP and 
HR=1.11 (1.02-1.22) for DBP, but not to the endometroid morphology (code 8380/3): 
HR=1.00 (0.96-1.05) for SBP and HR=1.02 (0.93-1.10) for DBP (Figure 2). In sub-group 
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analyses, the association for AC morphology was retained only at BMI>25kg/m
2
 and in never 
smokers (Supplementary Figure 1C,D,G,H). The differences between morphologies, 
however, would need further clarification, as the relative proportions of the two morphologies 
differed considerably between the individual countries in the EPIC cohort (Supplementary 
Table 3). 
Large European case-control and cohort studies (n>700 in each), although not 
accounting for specific morphologies, have consistently reported, in agreement with our 
findings, a higher risk of endometrial cancer with high BP [40, 43, 44], especially in obese 
women [43, 44], while a relatively smaller case-control study in the United States (n=469) 
found a higher risk only in women receiving thiazide diuretics [45]. Nevertheless, recent 
meta-analyses, have corroborated a positive association: RR=1.32 (1.12-1.56) (6 prospective 
studies, 1,1469 cases) [9], RR=1.81 (1.08–3.03) (5 studies, 3,112 cases) [10]. 
Cervical cancer 
For cervical SCC (n=145), but not for total cervical cancers (n=223), we found an 
inverse association (Figure 2), which was especially pronounced in women with 
BMI>25kg/m
2
 (n=68): HR=0.81 (0.71-0.93) for SBP and HR=0.74 (0.57-0.95) for DBP 
(Supplementary Figure 1C,D), whilst we found no evidence for association of BP with 
cervical AC (n=37) and a positive association for the remaining morphologies (n=41): 
HR=1.28 (1.10-1.48) for SBP and HR=1.53 (1.17-2.01) for DBP, which would have 
contributed to absence of an overall association for total cervical cancers, but with a small 
number of cases, this could be a chance finding. 
In contrast to our findings, Stocks et al. reported a higher risk of total cervical cancer 
in the Me-Can study (n=424): HR=1.17 (1.01-1.34) per 10mmHg higher mid-BP [3]. Further, 
Ulmer et al. examined individual morphological subtypes and reported, similar to esophageal 
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cancer, a positive association for cervical SCC (n=337): HR=1.28 (1.05-1.57) per SD higher 
mid-BP, but not for cervical AC (n=59): HR=1.09 (0.65-1.83) [46]. 
Prostate cancer 
Our study, based on a reasonably large number of incident cases (n=5,848), provided 
no evidence for association of SBP or DBP with the risk of prostate cancer: HR=0.99 (0.98-
1.01) for SBP and HR=1.01 (0.99-1.04) for DBP, except for some weak inverse association, 
mainly with SBP, which was found only in never smokers (n=1937): HR=0.97 (0.95-1.00). 
Contrary to our findings, the CONOR study (n=1974) [47] has reported a weak 
positive association between SBP and DBP and the risk of prostate cancer and recent meta-
have confirmed this [11, 14]. Based on 10 studies (n=4343), Esposito et al. reported RR=1.15 
(1.01-1.30) [11] and Gacci et al. (7 studies) reported RR=1.10 (1.01-1.19) [14]. However, the 
Me-Can study (n=6673) [48] found only a positive association of SBP and DBP with prostate 
cancer death, while Stocks et al. reported in the Swedish Construction Workers cohort an 
inverse association with the risk of total prostate cancer (n=10,002) and non-aggressive 
tumours (n=2817), but a positive association of DBP with the risk of aggressive tumours 
(n=2402)  [49]. In the light of these discrepancies, it would be important to examine further 
the impact of cancer aggressiveness or grading in EPIC, but this was beyond the scope of the 
current study. 
Blood and lymphoid cancers 
Our data revealed an inverse association of BP with the risk of all-type lymphomas 
(n=1058), and specifically with non-Hodgkin lymphomas (n=882): HR 0.96 (0.92-0.99) for 
SBP and borderline for DBP: HR=0.95 (0.89-1.02), whilst we found no evidence for 
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association with leukaemia (n=1308), or specifically with multiple myeloma (n=475) (Figure 
2). 
In the Me-Can study, Nagel et al. considered a total of 2,751 cases of myeloid and 
lymphoid neoplasms and their results did not support associations with mid-BP, except for a 
suggestion, based on a small number of cases (n=46), for an inverse association with the risk 
of T-cell non-Hodgkin lymphomas in men: HR=0.54 (0.29-1.01) [50]. Lymphoid cells are 
closely involved in inflammatory processes and recent studies have specifically linked T-cell 
subtypes with vascular remodelling and the development of hypertension [51], so there may 
be some mechanistic explanation, but this would need a more detailed investigation. 
Skin cancer 
We found evidence for a positive association with the risk of skin SCC for DBP 
(n=1399): HR=1.07 (1.02-1.13) and for antihypertensive treatment among hypertensive 
individuals: HR=1.45 (1.22-1.72). 
The Me-Can project also reported higher risk of skin SCC, but only in men (n=566): 
HR=1.11 (0.95–1.31) for one SD higher mid-BP and not in women (n=286): HR=0.95 (0.76-
1.19) [52]. Several studies have also reported higher risk in association with antihypertensive 
drugs, especially diuretics [53], but there were no sufficient treatment details in EPIC to 
explore further. 
Sensitivity analyses 
Excluding the first two years of follow-up did not have material influence on the 
findings (Supplementary Figure 2), except for abolishing the inverse association for cervical 
SCC (without changing it to positive), which may be the result of selection bias introduced by 
the exclusion. However, crude HRs (unadjusted) (Supplementary Figure 3) had indicated 
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some associations, which were lost or mitigated after adjustment for confounders. Thus, 
crude HRs indicated positive associations of SBP and DBP not only with esophageal SCC or 
the endometroid cancer morphology in corpus uteri, but also of the AC morphology in both 
locations, and further positive associations of DBP with gastric cancer (total and AC 
morphology) and of SBP, not only DBP, with cancers of the rectum and rectosigmoid 
junction, as well as with colon cancer. Additionally, crude HRs indicated positive 
associations of SBP and DBP with bladder cancer, of SBP with liver cancer (accountable for 
only by HCC) and of DBP with multiple myeloma. In addition, in the absence of adjustment 
for confounders a weak inverse association was observed for SBP with prostate cancer (SBP 
only) and DBP with lung AC. Associations observed only in crude and not in adjusted HR 
estimates suggest that the differences in the selection of adjustment variables in our and other 
studies may be responsible for some of the discrepancies in the findings. Of note, we have 
included adjustment for dietary factors, information on which was either not available or not 
included in the analyses in other published studies. This may be of particular relevance to 
cancers of the gastrointestinal tract. Similarly, we have used detailed information on 
reproductive factors in women, although adjustment did not affect our findings for breast and 
cervical cancers (Supplementary Figure 3). 
Strengths and limitations 
Our study has several strengths and limitations. Major advantages are the prospective 
design and the large sample size, including several European countries. Furthermore, BP was 
measured by trained personnel and was not self-reported. Detailed information on lifestyle, 
diet and, in women, reproductive history and hormonal treatments was also available, 
enabling adjustment for potential confounders and shared risk factors. 
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The main limitation of our study is that BP was measured only at one timepoint. 
Moreover, specific information on the type of antihypertensive medications in treated 
individuals was unavailable. Theoretically, antihypertensive treatment could lead to a lower 
“observed” BP, i.e. measured during the investigation, compared to the “underlying” BP, i.e. 
the BP that could be reached without treatment. If high BP is causally associated with cancer, 
controlling BP would mitigate the association, but if high BP and cancer share common 
mechanisms, the association would remain when BP is controlled, unless treatment targets 
the mechanism of BP development. In practice, however, a single timepoint measurement 
may not be representative of the commonly “observed” BP and this applies to untreated and 
treated individuals alike. Individuals receiving treatment are also likely to have a more 
sustained high BP, confirmed by a doctor. Treated individuals in our study showed, indeed, 
considerably higher SBP (mean difference 19.8mmHg (95% CI 19.6-20.1)) and DBP 
(9.5mmHg (9.4-9.6)) compared to cohort participants without antihypertensive treatment and 
even showed marginally higher SBP (1.2mmHg (1.0-1.4)) and DBP (0.4mmHg (0.3-0.5)) 
compared to untreated hypertensive individuals (self-reported or with “observed” high BP 
(Table 1)). Therefore, when there was a positive association for both hypertension and 
antihypertensive treatment, as for kidney cancer, we could not discriminate associations 
related to the severity and duration of high BP from association related to the administration 
of antihypertensive medication (Figure 3). Nevertheless, a positive association only for 
treated compared to untreated hypertension, as for cancers of the renal pelvis and ureter, 
might be more suggestive of the involvement of treatment (Figure 3). There is a growing 
body of literature evaluating associations between antihypertensive medication and cancer 
development, but with overall inconclusive findings. An involvement of drugs in cancer 
pathogenesis is possible, because they are exogenous chemical compounds administered 
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often for very long time [54], but we have not reviewed this literature, because our study 
could not contribute reliably to the debate. 
Finally, information about potential confounders and shared risk factors was self-
reported, which may have contributed to misclassification bias and there are always 
potentially unmeasured risk factors, which may result in residual confounding. 
CONCLUSIONS 
The results of our study, involving over 300,000 participants, are largely compatible 
with published studies. We confirmed a positive association between BP and RCC and 
additionally found a positive association of BP with malignant cancers in several anatomical 
cites, including postmenopausal breast and colon cancers, and with specific morphologies, 
i.e. SCC in the upper aero-digestive tract and the skin or AC in corpus uteri and other 
unspecified locations. We also found an inverse association of BP with the risk of non-
Hodgkin lymphomas and cervical SCC. These associations, however, are mainly weak and 
future research is required to clarify potential shared mechanisms. Admittedly, observations 
based on smaller number of cases could be chance findings, but they could also give some 
directions for further studies. 
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FIGURE CAPTIONS 
Figure 1 Flow diagram for EPIC participants included in the current study 
n – number of participants; ca – number of cancer cases. 
Figure 2 Forest plot of hazard ratios for continuous systolic and diastolic blood pressure 
AC – adenocarcinoma; CNS – central nervous system; HCC – hepatocellular carcinoma; 
SCC – squamous cell carcinoma; SmallCC – small cell carcinoma; Vertical order – 
determined by the hazard ratio estimates for systolic blood pressure (SBP) of the main 
anatomical locations (dot symbols), each followed by the relevant specific locations or 
morphologies marked with ^ (+ symbols) (other locations, not included in those specified, 
are shown last); Hazard ratios – estimates (95% confidence intervals) (per 10mmHg higher 
blood pressure) derived from Cox proportional hazards models, stratified by study centre and 
age at recruitment (5-year categories) and adjusted for potential confounders and risk factors 
listed in Supplementary Table 2). For cervical AC (n=37): HR=0.96 (0.79-1.17) for SBP and 
HR=0.84 (0.59-1.19) for DBP and for other morphology in the cervix (non-SCC and non-
AC) (n=41): HR=1.28 (1.10-1.48) for SBP and HR=1.53 (1.17-2.01) for DBP (considered 
only in the main analyses and excluded to avoid the larger confidence intervals dominating 
the plot); * p<0.05, ** p<0.005. 
Figure 3 Forest plot of hazard ratios for dichotomous hypertension and 
antihypertensive treatment 
AC – adenocarcinoma; CNS – central nervous system; HCC – hepatocellular carcinoma; 
SCC – squamous cell carcinoma; SmallCC – small cell carcinoma; Hypertension – defined 
as systolic blood pressure (SBP) ≥140 mmHg, or diastolic BP (DBP) ≥90 mmHg at the BP 
measurement visit, or self-reported history of hypertension; Antihypertensive treatment 
status – either self-reported or no treatment assumed if there was self-reported absence of 
diagnosis of hypertension; Cases – numbers per group (hypertension / no hypertension & 
Christakoudi & Kakourou et al. HT and CA in EPIC 
treated / untreated hypertension); Vertical order – determined by the hazard ratio estimates 
for SBP of the main anatomical locations (dot symbols), each followed by the relevant 
specific locations or morphologies marked with ^ (+ symbols) (as per Figure 2) (other 
locations, not included in those specified, are shown last); Hazard ratios – estimates (95% 
confidence intervals) (per 10 mmHg higher BP) were derived from Cox proportional hazards 
models, stratified by study centre and age at recruitment (5-year categories) and adjusted for 
potential confounders and risk factors listed in Supplementary Table 2. For cervical AC 
(n=37): HR=1.23 (0.58-2.06) and for other morphology in the cervix (non-SCC and non-AC) 
(n=41): HR=1.82 (0.92-3.63) (considered only in the main analyses and omitted from the plot 
to avoid the larger confidence intervals dominating the plot); * p<0.05, ** p<0.005. 
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Table 1 Baseline demographic, lifestyle and reproductive characteristics by 
hypertension and treatment status  
Characteristics  
(men and women) 
Total No 
hypertension 
Hypertension Untreated 
hypertension 
Treated 
hypertension 
Cohort size 307318 174179 133139 73714 37017 
Female 194727 (63.4) 117264 (67.3) 77463 (58.2) 41779 (56.7) 23736 (64.1) 
Age at recruitment, years 52.5 (9.9) 49.8 (9.8) 56.1 (8.7) 54.9 (8.6) 57.8 (7.6) 
Body Mass Index, kg/m2 25.8 (4.2) 24.8 (3.7) 27.1 (4.5) 26.7 (4.3) 28.2 (4.7) 
Alcohol intake, g/day 12.4 (17.1) 11.2 (15.2) 13.9 (19.2) 15.4 (20.2) 12.3 (18.0) 
Fruit consumption, g/day 230.6 (176.7) 235.2 (182.3) 224.6 (169.0) 226.3 (172.6) 230.9 (164.4) 
Vegetable consumption, g/day 200.9 (145.4) 205.0 (149.9) 195.6 (139.2) 190.9 (138.4) 195.9 (143.6) 
Red meat consumption, g/day 48.2 (36.3) 46.5 (35.7) 50.5 (37.0) 53.1 (37.7) 47.4 (34.0) 
Blood pressure, mmHg 
Systolic blood pressure 131.5 (19.7) 119.4 (10.9) 147.3 (17.4) 146.7 (15.9) 147.9 (20.0) 
Diastolic blood pressure 81.1 (10.9) 75.2 (7.5) 88.8 (9.8) 88.6 ( 9.1) 89.0 (10.6) 
Diabetes 
Self-reported diabetes 8588 (2.8) 2516 (1.4) 6072 (4.6) 2410 (3.3) 3067 (8.3) 
Missing information 30147 (9.8) 16247 (9.3) 13900 (10.4) 615 (0.8) 657 (1.8) 
Smoking status 
Never smoker 141931 (46.2) 80450 (46.2) 61481 (46.2) 33057 (44.8) 18603 (50.3) 
Former smoker 86314 (28.1) 45575 (26.2) 40739 (30.6) 21901 (29.7) 11154 (30.1) 
Current smoker (≤ 20 pack-years) 32226 (10.5) 21711 (12.5) 10515 (7.9) 6539 (8.9) 2716 (7.3) 
Current smoker (> 20 pack-years) 34907 (11.4) 19428 (11.2) 15479 (11.6) 9777 (13.3) 3655 (9.9) 
Missing information 11940 ( 3.9) 7015 (4.0) 4925 (3.7) 2440 (3.3) 889 (2.4) 
Physical activity 
Inactive 67194 (21.9) 32680 (18.8) 34514 (25.9) 16013 (21.7) 11191 (30.2) 
Moderately inactive 100295 (32.6) 57476 (33.0) 42819 (32.2) 23828 (32.3) 12268 (33.1) 
Moderately active 70977 (23.1) 42530 (24.4) 28447 (21.4) 16954 (23.0) 7300 (19.7) 
Active 62152 (20.2) 36956 (21.2) 25196 (18.9) 15696 (21.3) 6021 (16.3) 
Missing information 6700 ( 2.2) 4537 (2.6) 2163 (1.6) 1223 (1.7) 237 (0.6) 
Education 
None 9377 ( 3.1) 3478 (2.0) 5899 (4.4) 2863 (3.9) 2973 (8.0) 
Primary school completed 90254 (29.4) 43392 (24.9) 46862 (35.2) 25274 (34.3) 14288 (38.6) 
Technical/professional school 77398 (25.2) 43025 (24.7) 34373 (25.8) 18676 (25.3) 9033 (24.4) 
Secondary school 53830 (17.5) 35179 (20.2) 18651 (14.0) 11377 (15.4) 4730 (12.8) 
Longer education (inc. University) 67606 (22.0) 43999 (25.3) 23607 (17.7) 14246 (19.3) 5875 (15.9) 
Missing information 8853 ( 2.9) 5106 (2.9) 3747 (2.8) 1278 (1.7) 118 (0.3) 
Age at first menstrual period * 
< 12 years 27085 (13.9) 16544 (14.1) 10541 (13.6) 5521 (13.2) 3116 (13.1) 
>=12 and < 15 years 125828 (64.6) 76353 (65.1) 49475 (63.9) 27400 (65.6) 15450 (65.1) 
>= 15 years 32391 (16.6) 17996 (15.3) 14395 (18.6) 7842 (18.8) 4618 (19.5) 
Missing information 9423 ( 4.8) 6371 (5.4) 3052 (3.9) 1016 (2.4) 552 (2.3) 
Age at first full term pregnancy* 
≤ 21 years 36839 (18.9) 20636 (17.6) 16203 (20.9) 8514 (20.4) 5607 (23.6) 
> 21 and ≤ 30 years 106230 (54.6) 62619 (53.4) 43611 (56.3) 23884 (57.2) 13515 (56.9) 
≥ 30 years 15709 ( 8.1) 9715 (8.3) 5994 (7.7) 3391 (8.1) 1689 (7.1) 
Missing information 35949 (18.5) 24294 (20.7) 11655 (15.0) 5990 (14.3) 2925 (12.3) 
Full-term pregnancies * 
None 25571 (13.1) 16963 (14.5) 8608 (11.1) 4966 (11.9) 2397 (10.1) 
One 28796 (14.8) 17156 (14.6) 11640 (15.0) 6350 (15.2) 3656 (15.4) 
Two 75357 (38.7) 45696 (39.0) 29661 (38.3) 16246 (38.9) 9280 (39.1) 
Three 33031 (17.0) 18740 (16.0) 14291 (18.4) 7483 (17.9) 4664 (19.6) 
Four or more 14897 ( 7.7) 7360 (6.3) 7537 (9.7) 3601 (8.6) 2832 (11.9) 
Missing information 17075 ( 8.8) 11349 (9.7) 5726 (7.4) 3133 (7.5) 907 (3.8) 
Menopausal status * 
Pre-menopausal 58190 (29.9) 45853 (39.1) 12337 (15.9) 7856 (18.8) 2450 (10.3) 
Post-menopausal 96806 (49.7) 46876 (40.0) 49930 (64.5) 25486 (61.0) 16640 (70.1) 
Peri-menopausal or unknown 33371 (17.1) 21490 (18.3) 11881 (15.3) 6918 (16.6) 3292 (13.9) 
Surgical post-menopausal 6360 ( 3.3) 3045 (2.6) 3315 (4.3) 1519 (3.6) 1354 (5.7) 
Continues on next page 
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Table 1 (continued) 
Reproductive characteristics 
(women) 
Total No 
hypertension 
Hypertension Untreated 
hypertension 
Treated 
hypertension 
Age at menopause * 
< 40 years 4301 ( 2.2) 2106 (1.8) 2195 (2.8) 1067 (2.6) 769 (3.2) 
≥ 40 and ≤ 46 years 18912 ( 9.7) 9058 (7.7) 9854 (12.7) 4754 (11.4) 3650 (15.4) 
> 46 and ≤ 50 years 31996 (16.4) 15578 (13.3) 16418 (21.2) 8510 (20.4) 5579 (23.5) 
> 50 and ≤ 56 years 29427 (15.1) 13238 (11.3) 16189 (20.9) 8327 (19.9) 5619 (23.7) 
> 56 years 1997 ( 1.0) 753 (0.6) 1244 (1.6) 595 (1.4) 469 (2.0) 
Missing or not applicable 108094 (55.5) 76531 (65.3) 31563 (40.7) 18526 (44.3) 7650 (32.2) 
Oral contraceptive use * 
Never 82568 (42.4) 43393 (37.0) 39175 (50.6) 20706 (49.6) 12755 (53.7) 
Former 91622 (47.1) 58870 (50.2) 32752 (42.3) 18294 (43.8) 9916 (41.8) 
Current 10050 ( 5.2) 7434 (6.3) 2616 (3.4) 1829 (4.4) 594 (2.5) 
Missing information 10487 ( 5.4) 7567 (6.5) 2920 (3.8) 950 (2.3) 471 (2.0) 
Hormone replacement therapy * 
Never 129049 (66.3) 79952 (68.2) 49097 (63.4) 26920 (64.4) 14842 (62.5) 
Former 16259 ( 8.3) 8638 (7.4) 7621 (9.8) 3937 (9.4) 2598 (10.9) 
Current 30133 (15.5) 17724 (15.1) 12409 (16.0) 6596 (15.8) 3891 (16.4) 
Missing information 19286 ( 9.9) 10950 (9.3) 8336 (10.8) 4326 (10.4) 2405 (10.1) 
* Reproductive characteristics in women; Categorical variables: number of individuals
(percentage from total number in category (for reproductive factors in women only)); 
Continuous variables: mean (standard deviation). 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort 
(n= 521 324, ca= 60 230)
Recruitment: 1991 – 1999 (n=7 up to 2001) ; Follow-up: recruitment to 2013
Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Prevalent cancer at recruitment (n= 25 184, ca= 3770)
Blood pressure measured after malignant cancer diagnosis or administrative censoring (n=631, ca=400)
Energy intake to estimated energy requirement ratio (top/bottom 1% of cohort) (n= 9573, ca= 1084)
Main analysis dataset 
(n= 307 318, ca= 39 298)
Lifestyle questionnaire not completed (n= 1277, ca= 104)
Dietary questionnaire not completed (n= 4982, ca= 811)
Blood pressure measurements missing (n= 168 211, ca= 14 761)
France (n= 47 600 (71%), ca= 3456 (73%)); Germany (n= 15 509 (32%), ca= 1708 (40%)); 
Norway (n=33 975 (all participants), ca=3032); Spain (n=33 709 (84%), ca=3556 (85%) including all participants 
from Asturias (n=8279, ca=791) and Navarra (n=7777, ca=987)); 
United Kingdom (n= 35 223 (47%), ca= 2777 (32%)); Other countries (n= 2195 (1%), ca= 232 (0.8%))
≤ 53 years
n= 153 303
ca= 12 018
Age at recruitment
> 53 years
n= 154 015
ca= 27 280
Smoking status
n= 301 857
ca= 35 941
Ever 
smokers
n= 160 623
ca= 23 704
Antihypertensive 
treatment
No treatment
n= 227 336
ca= 26 864
Treated
n= 37 017
ca= 5 538
Sex
Men
n= 112 591
ca= 17 452
Women
n= 194 727 
ca= 21 846
Alcohol intake
≤ 12 g/day
n= 205 214
ca= 24 429
> 12 g/day
n= 102 104
ca= 14 869
First 2 years 
of follow-up
excluded Never 
smokers
n= 141 931
ca= 15 120
BMI
≤ 25 kg/m2
n= 146 326
ca= 17 441
> 25 kg/m2
n= 160 992
ca= 21 857
Date of diagnosis missing (n= 20) or follow-up time missing (n= 4128, ca= 2)
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
Head and neck
Digestive system
Respiratory system
Urinary system
Reproductive system
Skin
Nervous and endocrine system
Hematopoietic system
Other
Any cancer (39298)
Head and neck (combined) (683)
Esophagus (387)
Stomach (738)
Colorectal (4625)
Liver and bile ducts (653)
Pancreas (990)
Lung (combined) (3229)
Kidney (758)
Renal pelvis and ureter (112)
Bladder (1192)
Prostate (5848)
Breast (female) (8154)
Ovary (1007)
Corpus uteri (1164)
Cervix uteri (223)
Anogenital (not cervix) (244)
Skin SCC (1399)
Melanoma (skin) (1617)
Brain and CNS (591)
Thyroid (420)
Leukemia (1308)
Lymphoma (all types) (1058)
Other location AC (406)
Other location or other morphology (2492)
^ Mouth and oropharynx (332)
^ Larynx (239)
^ Esophageal AC (176)
^ Esophageal SCC (149)
^ Gastric AC (403)
^ Colon (3003)
^ Rectum and rectosigmoid junction (1622)
^ HCC (191)
^ Gallbladder and  bile ducts (346)
^ Lung AC (1130)
^ Lung SCC (613)
^ Lung SmallCC (379)
^ Lung (other morphology) (1107)
^ Breast pre−menopausal (256)
^ Breast post−menopausal (4786)
^ Uterine AC (488)
^ Endometroid AC (546)
^ Cervix SCC (145)
^ Anogenital SCC (173)
^ Glioblastoma (297)
^ Multiple myeloma (475)
^ Non−Hodgkin lymphomas (882)
1.01 (1.01−1.02) **
1.08 (1.04−1.12) **
1.07 (1.01−1.13) *
1.12 (1.04−1.19) **
1.09 (1.03−1.15) **
1.04 (0.96−1.13)
1.16 (1.07−1.26) **
1.00 (0.96−1.05)
1.01 (0.95−1.06)
1.01 (0.99−1.03)
1.01 (0.99−1.03)
1.01 (0.98−1.04)
1.01 (0.97−1.05)
1.05 (0.97−1.14)
0.99 (0.93−1.05)
1.01 (0.98−1.05)
1.03 (1.01−1.05) **
1.02 (0.99−1.06)
0.99 (0.95−1.03)
1.04 (0.99−1.10)
1.06 (1.02−1.09) **
1.12 (1.08−1.16) **
1.05 (0.95−1.16)
1.01 (0.98−1.05)
0.99 (0.98−1.01)
1.03 (1.01−1.04) **
1.07 (0.97−1.18)
1.02 (1.01−1.04) **
0.99 (0.96−1.03)
1.04 (1.00−1.07) *
1.06 (1.01−1.12) *
1.00 (0.96−1.05)
0.99 (0.91−1.06)
0.91 (0.82−1.00)
0.98 (0.92−1.06)
1.02 (0.94−1.11)
1.01 (0.98−1.04)
1.01 (0.98−1.04)
1.00 (0.95−1.05)
0.97 (0.91−1.04)
1.02 (0.96−1.08)
0.99 (0.96−1.02)
0.99 (0.94−1.05)
0.97 (0.93−1.00) *
0.96 (0.92−0.99) *
1.08 (1.03−1.14) **
1.02 (0.99−1.04)
1.02 (1.01−1.03) **
1.09 (1.01−1.17) *
1.13 (1.02−1.25) *
1.11 (0.98−1.25)
1.15 (1.04−1.26) **
1.08 (0.94−1.24)
1.31 (1.13−1.51) **
1.06 (0.98−1.13)
1.05 (0.96−1.16)
1.04 (1.01−1.07) **
1.06 (1.02−1.10) **
1.01 (0.96−1.06)
0.98 (0.90−1.05)
0.92 (0.80−1.06)
1.01 (0.91−1.12)
1.01 (0.95−1.08)
1.00 (0.97−1.04)
0.98 (0.92−1.04)
0.97 (0.89−1.04)
0.99 (0.90−1.10)
1.05 (0.99−1.11)
1.22 (1.14−1.31) **
0.97 (0.81−1.17)
1.00 (0.95−1.06)
1.01 (0.99−1.04)
1.03 (1.01−1.06) **
1.06 (0.92−1.21)
1.04 (1.01−1.07) *
1.00 (0.94−1.06)
1.06 (1.00−1.12) *
1.11 (1.02−1.22) *
1.02 (0.93−1.10)
0.98 (0.86−1.12)
0.88 (0.74−1.05)
0.97 (0.86−1.11)
1.00 (0.86−1.16)
1.07 (1.02−1.13) *
1.00 (0.95−1.05)
0.97 (0.90−1.06)
0.96 (0.85−1.07)
1.03 (0.93−1.14)
0.97 (0.92−1.03)
1.01 (0.92−1.11)
0.96 (0.90−1.02)
0.95 (0.89−1.02)
1.03 (0.93−1.13)
1.02 (0.98−1.06)
Cancer type (cases) ^ subtype Systolic blood pressure (10 mmHg) Diastolic blood pressure (10 mmHg)
Hazard ratio 0.8 0.9 1.0 1.1 1.2 1.3 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
Head and neck
Digestive system
Respiratory system
Urinary system
Reproductive system
Skin
Nervous and endocrine system
Hematopoietic system
Other
Any cancer (20374 / 18924 & 5538 / 10895)
Head and neck (combined) (382 / 301 & 106 / 212)
Esophagus (227 / 160 & 37 / 119)
Stomach (401 / 337 & 122 / 214)
Colorectal (2521 / 2104 & 678 / 1327)
Liver and bile ducts (390 / 263 & 129 / 200)
Pancreas (553 / 437 & 152 / 298)
Lung (combined) (1707 / 1522 & 409 / 970)
Kidney (465 / 293 & 159 / 217)
Renal pelvis and ureter (59 / 53 & 23 / 20)
Bladder (688 / 504 & 179 / 386)
Prostate (3376 / 2472 & 844 / 1839)
Breast (female) (3509 / 4645 & 1013 / 1918)
Ovary (453 / 554 & 112 / 241)
Corpus uteri (624 / 540 & 219 / 291)
Cervix uteri (87 / 136 & 28 / 42)
Anogenital (not cervix) (131 / 113 & 35 / 77)
Skin SCC (815 / 584 & 221 / 392)
Melanoma (skin) (771 / 846 & 197 / 426)
Brain and CNS (291 / 300 & 71 / 149)
Thyroid (161 / 259 & 57 / 88)
Leukemia (695 / 613 & 205 / 351)
Lymphoma (all types) (504 / 554 & 119 / 273)
Other location AC (238 / 168 & 53 / 147)
Other location or other morphology (1326 / 1166 & 370 / 698)
^ Mouth and oropharynx (180 / 152 & 42 / 109)
^ Larynx (142 / 97 & 50 / 66)
^ Esophageal AC (106 / 70 & 12 / 49)
^ Esophageal SCC (90 / 59 & 16 / 54)
^ Gastric AC (210 / 193 & 53 / 112)
^ Colon (1656 / 1347 & 457 / 862)
^ Rectum and rectosigmoid junction (865 / 757 & 221 / 465)
^ HCC (124 / 67 & 42 / 60)
^ Gallbladder and  bile ducts (196 / 150 & 60 / 103)
^ Lung AC (573 / 557 & 138 / 350)
^ Lung SCC (327 / 286 & 74 / 173)
^ Lung SmallCC (214 / 165 & 56 / 116)
^ Lung (other morphology) (593 / 514 & 141 / 331)
^ Breast pre−menopausal (36 / 220 & 5 / 18)
^ Breast post−menopausal (2517 / 2269 & 783 / 1316)
^ Uterine AC (274 / 214 & 93 / 132)
^ Endometroid AC (277 / 269 & 96 / 131)
^ Cervix SCC (51 / 94 & 17 / 25)
^ Anogenital SCC (93 / 80 & 23 / 56)
^ Glioblastoma (144 / 153 & 37 / 71)
^ Multiple myeloma (254 / 221 & 87 / 125)
^ Non−Hodgkin lymphomas (409 / 473 & 96 / 226)
1.03 (1.01−1.05) *
1.21 (1.03−1.42) *
1.15 (0.91−1.45)
1.37 (1.04−1.80) *
1.20 (0.97−1.49)
1.11 (0.80−1.52)
1.47 (1.04−2.09) *
0.94 (0.80−1.10)
0.83 (0.67−1.02)
1.00 (0.94−1.07)
1.02 (0.94−1.10)
0.97 (0.88−1.08)
1.09 (0.92−1.29)
1.18 (0.86−1.63)
1.07 (0.85−1.35)
1.11 (0.97−1.27)
1.04 (0.97−1.12)
1.04 (0.91−1.17)
0.95 (0.80−1.13)
1.25 (1.01−1.55) *
1.04 (0.91−1.17)
1.41 (1.21−1.65) **
0.93 (0.63−1.39)
1.02 (0.91−1.16)
1.01 (0.96−1.07)
1.03 (0.98−1.08)
0.91 (0.63−1.32)
1.06 (1.00−1.13) *
0.97 (0.85−1.11)
1.16 (1.02−1.32) *
1.21 (0.99−1.47)
1.11 (0.92−1.33)
0.91 (0.68−1.23)
0.71 (0.49−1.03)
1.12 (0.85−1.47)
1.17 (0.85−1.62)
1.09 (0.97−1.22)
1.00 (0.90−1.12)
0.97 (0.81−1.15)
0.92 (0.72−1.17)
1.04 (0.84−1.29)
1.01 (0.90−1.13)
0.98 (0.81−1.19)
0.84 (0.74−0.96) *
0.81 (0.70−0.93) **
1.30 (1.05−1.60) *
1.02 (0.94−1.11)
1.07 (1.04−1.11) **
1.34 (1.05−1.71) *
0.96 (0.66−1.39)
2.29 (1.55−3.38) **
0.84 (0.57−1.23)
0.58 (0.30−1.12)
0.86 (0.48−1.53)
1.06 (0.84−1.35)
1.05 (0.75−1.47)
1.00 (0.91−1.10)
1.00 (0.89−1.13)
1.00 (0.85−1.19)
1.12 (0.88−1.42)
1.19 (0.78−1.83)
1.02 (0.72−1.43)
0.98 (0.80−1.21)
0.98 (0.87−1.10)
0.92 (0.75−1.13)
1.06 (0.79−1.40)
1.17 (0.83−1.63)
0.93 (0.76−1.15)
1.43 (1.15−1.78) **
2.21 (1.18−4.12) *
0.97 (0.80−1.17)
1.08 (0.99−1.17)
1.03 (0.95−1.12)
           −
1.04 (0.95−1.15)
0.87 (0.69−1.11)
1.32 (1.09−1.58) **
1.22 (0.92−1.61)
1.27 (0.96−1.69)
1.30 (0.78−2.16)
1.33 (0.69−2.57)
0.85 (0.56−1.30)
0.81 (0.48−1.35)
1.45 (1.22−1.72) **
1.12 (0.94−1.34)
1.03 (0.76−1.38)
1.17 (0.77−1.77)
1.22 (0.85−1.75)
1.14 (0.95−1.37)
1.28 (0.96−1.71)
0.99 (0.79−1.24)
0.97 (0.76−1.25)
0.79 (0.57−1.09)
1.11 (0.97−1.26)
Cancer type (cases) ^ subtype Hypertension vs No hypertension Treated vs Untreated hypertension
Hazard ratio 0.5 1.0 1.5 2.0 0.5 1.0 1.5 2.0 2.5 3.0
Christakoudi & Kakourou et al. HT and CA in EPIC 
Novelty and Impact: 
Is there a link between high blood pressure and cancer? In this large, prospective study, the 
authors found that hypertension is indeed associated with a moderate increase in risk for 
several cancers, including renal, esophageal, head and neck, skin, colon, post-menopausal 
breast cancer, and uterine cancer. These results may potentially enhance screening and risk 
assessment. Further research may also identify shared mechanisms for both hypertension and 
cancer, such as inflammation, lipid peroxidation, etc. 
